









市场行情
/
股票
/
nasdaq-vrtx
/

福泰制药

VRTX

447.380USD

-2.140-0.48%

收盘 12/18, 16:00（美东）报价延迟15分钟

113.61B总市值

31.27市盈率 TTM



福泰制药

447.380

-2.140-0.48%

概览公司财务分析

概览

公司

财务

分析

关于福泰制药公司

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

福泰制药简介



公司代码VRTX

公司名称Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

CEOKewalramani (Reshma)

员工数量6100

证券类型Ordinary Share

年结日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02210

电话16173416393

网址https://www.vrtx.com/

公司代码VRTX

上市日期Jul 24, 1991

CEOKewalramani (Reshma)

福泰制药公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.80K

-14.85%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

15.31K

-2.22%

Mr. Lloyd A. Carney

Independent Director

6.32K

-11.24%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-5.51%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

名称

名称/职务

职务

持股

持股变动

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.80K

-14.85%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

地区USD

名称

营收

占比

United States

1.83B

62.08%

Europe

910.90M

30.94%

Other

205.60M

6.98%

业务

地区

业务USD

名称

营收

占比

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

股东统计

更新时间: 11月15日周六

持股股东

股东类型

持股股东

占比

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.50%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

其他

63.49%

持股股东

占比

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.50%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

其他

63.49%

股东类型

持股股东

占比

Investment Advisor

60.06%

Investment Advisor/Hedge Fund

28.01%

Research Firm

2.35%

Pension Fund

2.27%

Bank and Trust

2.08%

Sovereign Wealth Fund

1.50%

Hedge Fund

1.14%

Individual Investor

0.14%

Insurance Company

0.09%

其他

2.36%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

2933

249.27M

98.24%

-2.14M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Capital World Investors

28.73M

11.21%

+198.84K

+0.70%

Jun 30, 2025

The Vanguard Group, Inc.

23.86M

9.31%

+479.23K

+2.05%

Jun 30, 2025

Capital Research Global Investors

16.11M

6.28%

+1.57M

+10.81%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

14.15M

5.52%

+156.31K

+1.12%

Jun 30, 2025

State Street Investment Management (US)

11.78M

4.59%

-13.43K

-0.11%

Jun 30, 2025

Geode Capital Management, L.L.C.

5.93M

2.31%

+166.99K

+2.90%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

5.26M

2.05%

-18.59K

-0.35%

Aug 31, 2025

Wellington Management Company, LLP

4.81M

1.88%

-641.36K

-11.76%

Jun 30, 2025

Capital International Investors

2.64M

1.03%

+1.99M

+305.59%

Jun 30, 2025

AllianceBernstein L.P.

4.38M

1.71%

+424.81K

+10.75%

Jun 30, 2025

持股ETF



更新时间: 12月5日周五

机构名称

占比

VanEck Biotech ETF

9.71%

ProShares Ultra Nasdaq Biotechnology

8.83%

Invesco Nasdaq Biotechnology ETF

8.76%

iShares Biotechnology ETF

7.43%

Invesco Biotechnology & Genome ETF

5.35%

Natixis Loomis Sayles Focused Growth ETF

4.48%

First Trust NASDAQ Pharmaceuticals ETF

4.23%

First Trust NYSE Arca Biotechnology Index Fund

3.5%

Franklin Genomic Advancements ETF

3.33%

Simplify Health Care ETF

3.25%

VanEck Biotech ETF

占比9.71%

ProShares Ultra Nasdaq Biotechnology

占比8.83%

Invesco Nasdaq Biotechnology ETF

占比8.76%

iShares Biotechnology ETF

占比7.43%

Invesco Biotechnology & Genome ETF

占比5.35%

Natixis Loomis Sayles Focused Growth ETF

占比4.48%

First Trust NASDAQ Pharmaceuticals ETF

占比4.23%

First Trust NYSE Arca Biotechnology Index Fund

占比3.5%

Franklin Genomic Advancements ETF

占比3.33%

Simplify Health Care ETF

占比3.25%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

福泰制药的前五大股东是谁？



福泰制药的前五大股东如下：
Capital World Investors持有股份：28.73M，占总股份比例：11.21%。
The Vanguard Group, Inc.持有股份：23.86M，占总股份比例：9.31%。
Capital Research Global Investors持有股份：16.11M，占总股份比例：6.28%。
BlackRock Institutional Trust Company, N.A.持有股份：14.15M，占总股份比例：5.52%。
State Street Investment Management (US)持有股份：11.78M，占总股份比例：4.59%。